全身性エリテマトーデス:治療薬開発パイプライン動向(2016年下半期版)

【英語タイトル】Systemic Lupus Erythematosus - Pipeline Review, H2 2016

Global Markets Directが出版した調査資料(DATA70209295)・商品コード:DATA70209295
・発行会社(調査会社):Global Markets Direct
・発行日:2016年11月16日
・ページ数:419
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における全身性エリテマトーデスの治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・全身性エリテマトーデスの概要
・全身性エリテマトーデス治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・全身性エリテマトーデスパイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・全身性エリテマトーデス治療薬開発に取り組んでいる企業:企業別製品パイプライン
・全身性エリテマトーデス治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Systemic Lupus Erythematosus – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus – Pipeline Review, H2 2016, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 22, 31, 36 and 7 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 9 and 1 molecules, respectively.Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
- The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 7
Systemic Lupus Erythematosus Overview 8
Therapeutics Development 9
Systemic Lupus Erythematosus – Therapeutics under Development by Companies 11
Systemic Lupus Erythematosus – Therapeutics under Investigation by Universities/Institutes 16
Systemic Lupus Erythematosus – Pipeline Products Glance 17
Systemic Lupus Erythematosus – Products under Development by Companies 20
Systemic Lupus Erythematosus – Products under Investigation by Universities/Institutes 27
Systemic Lupus Erythematosus – Companies Involved in Therapeutics Development 28
Systemic Lupus Erythematosus – Therapeutics Assessment 105
Drug Profiles 121
Systemic Lupus Erythematosus – Dormant Projects 381
Systemic Lupus Erythematosus – Discontinued Products 390
Systemic Lupus Erythematosus – Product Development Milestones 392
Appendix 405

List of Tables
Number of Products under Development for Systemic Lupus Erythematosus, H2 2016 22
Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H2 2016 23
Number of Products under Development by Companies, H2 2016 24
Number of Products under Development by Companies, H2 2016 (Contd..1) 25
Number of Products under Development by Companies, H2 2016 (Contd..2) 26
Number of Products under Development by Companies, H2 2016 (Contd..3) 27
Number of Products under Development by Companies, H2 2016 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H2 2016 29
Comparative Analysis by Late Stage Development, H2 2016 30
Comparative Analysis by Clinical Stage Development, H2 2016 31
Comparative Analysis by Early Stage Development, H2 2016 32
Products under Development by Companies, H2 2016 33
Products under Development by Companies, H2 2016 (Contd..1) 34
Products under Development by Companies, H2 2016 (Contd..2) 35
Products under Development by Companies, H2 2016 (Contd..3) 36
Products under Development by Companies, H2 2016 (Contd..4) 37
Products under Development by Companies, H2 2016 (Contd..5) 38
Products under Development by Companies, H2 2016 (Contd..6) 39
Products under Investigation by Universities/Institutes, H2 2016 40
Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H2 2016 41
Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H2 2016 42
Systemic Lupus Erythematosus - Pipeline by ACEA Biosciences, Inc., H2 2016 43
Systemic Lupus Erythematosus - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 44
Systemic Lupus Erythematosus - Pipeline by Actelion Ltd, H2 2016 45
Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH and Co KG, H2 2016 46
Systemic Lupus Erythematosus - Pipeline by Amgen Inc., H2 2016 47
Systemic Lupus Erythematosus - Pipeline by Anthera Pharmaceuticals Inc, H2 2016 48
Systemic Lupus Erythematosus - Pipeline by Argos Therapeutics, Inc., H2 2016 49
Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp., H2 2016 50
Systemic Lupus Erythematosus - Pipeline by Astellas Pharma Inc., H2 2016 51
Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, H2 2016 52
Systemic Lupus Erythematosus - Pipeline by Azano Pharmaceuticals Inc., H2 2016 53
Systemic Lupus Erythematosus - Pipeline by Biogen Inc, H2 2016 54
Systemic Lupus Erythematosus - Pipeline by Biotest AG, H2 2016 55
Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim GmbH, H2 2016 56
Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Company, H2 2016 57
Systemic Lupus Erythematosus - Pipeline by Celgene Corporation, H2 2016 58
Systemic Lupus Erythematosus - Pipeline by Cellular Biomedicine Group, Inc., H2 2016 59
Systemic Lupus Erythematosus - Pipeline by CuraVac, Inc., H2 2016 60
Systemic Lupus Erythematosus - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 61
Systemic Lupus Erythematosus - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2016 62
Systemic Lupus Erythematosus - Pipeline by Eisai Co., Ltd., H2 2016 63
Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Company, H2 2016 64
Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 65
Systemic Lupus Erythematosus - Pipeline by Genentech Inc, H2 2016 66
Systemic Lupus Erythematosus - Pipeline by Genosco, H2 2016 67
Systemic Lupus Erythematosus - Pipeline by Genovax S.r.l., H2 2016 68
Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H2 2016 69
Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 70
Systemic Lupus Erythematosus - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 71
Systemic Lupus Erythematosus - Pipeline by Iltoo Pharma, H2 2016 72
Systemic Lupus Erythematosus - Pipeline by ImmuNext, Inc., H2 2016 73
Systemic Lupus Erythematosus - Pipeline by Immungenetics AG, H2 2016 74
Systemic Lupus Erythematosus - Pipeline by Immunomedics, Inc., H2 2016 75
Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H2 2016 76
Systemic Lupus Erythematosus - Pipeline by Invion Limited, H2 2016 77
Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H2 2016 78
Systemic Lupus Erythematosus - Pipeline by Kadmon Corporation, LLC, H2 2016 79
Systemic Lupus Erythematosus - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 80
Systemic Lupus Erythematosus - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 81
Systemic Lupus Erythematosus - Pipeline by KPI Therapeutics, Inc., H2 2016 82
Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H2 2016 83
Systemic Lupus Erythematosus - Pipeline by LSK BioPartners, Inc., H2 2016 84
Systemic Lupus Erythematosus - Pipeline by MacroGenics, Inc., H2 2016 85
Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H2 2016 86
Systemic Lupus Erythematosus - Pipeline by Medestea Research & Production S.p.A., H2 2016 87
Systemic Lupus Erythematosus - Pipeline by MedImmune LLC, H2 2016 88
Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H2 2016 89
Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 90
Systemic Lupus Erythematosus - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 91
Systemic Lupus Erythematosus - Pipeline by Mount Tam Biotechnologies Inc, H2 2016 92
Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H2 2016 93
Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 94
Systemic Lupus Erythematosus - Pipeline by Nuevolution AB, H2 2016 95
Systemic Lupus Erythematosus - Pipeline by Omeros Corporation, H2 2016 96
Systemic Lupus Erythematosus - Pipeline by Parvus Therapeutics, Inc., H2 2016 97
Systemic Lupus Erythematosus - Pipeline by Pfizer Inc., H2 2016 98
Systemic Lupus Erythematosus - Pipeline by Principia Biopharma Inc., H2 2016 99
Systemic Lupus Erythematosus - Pipeline by Ra Pharmaceuticals, Inc., H2 2016 100
Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd., H2 2016 101
Systemic Lupus Erythematosus - Pipeline by Redx Pharma Plc, H2 2016 102
Systemic Lupus Erythematosus - Pipeline by Resolve Therapeutics, LLC, H2 2016 103
Systemic Lupus Erythematosus - Pipeline by Sanofi, H2 2016 104
Systemic Lupus Erythematosus - Pipeline by Sarepta Therapeutics, Inc., H2 2016 105
Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co., Ltd., H2 2016 106
Systemic Lupus Erythematosus - Pipeline by Seattle Genetics, Inc., H2 2016 107
Systemic Lupus Erythematosus - Pipeline by Shire Plc, H2 2016 108
Systemic Lupus Erythematosus - Pipeline by Stemline Therapeutics, Inc., H2 2016 109
Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 110
Systemic Lupus Erythematosus - Pipeline by TheraMAB LLC, H2 2016 111
Systemic Lupus Erythematosus - Pipeline by Therapix Biosciences Ltd., H2 2016 112
Systemic Lupus Erythematosus - Pipeline by Thunderbolt Pharma Inc, H2 2016 113
Systemic Lupus Erythematosus - Pipeline by TxCell SA, H2 2016 114
Systemic Lupus Erythematosus - Pipeline by UCB SA, H2 2016 115
Systemic Lupus Erythematosus - Pipeline by Xencor, Inc., H2 2016 116
Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd, H2 2016 117
Assessment by Monotherapy Products, H2 2016 118
Assessment by Combination Products, H2 2016 119
Number of Products by Stage and Target, H2 2016 121
Number of Products by Stage and Mechanism of Action, H2 2016 126
Number of Products by Stage and Route of Administration, H2 2016 131
Number of Products by Stage and Molecule Type, H2 2016 133
Systemic Lupus Erythematosus - Dormant Projects, H2 2016 394
Systemic Lupus Erythematosus - Dormant Projects (Contd..1), H2 2016 395
Systemic Lupus Erythematosus - Dormant Projects (Contd..2), H2 2016 396
Systemic Lupus Erythematosus - Dormant Projects (Contd..3), H2 2016 397
Systemic Lupus Erythematosus - Dormant Projects (Contd..4), H2 2016 398
Systemic Lupus Erythematosus - Dormant Projects (Contd..5), H2 2016 399
Systemic Lupus Erythematosus - Dormant Projects (Contd..6), H2 2016 400
Systemic Lupus Erythematosus - Dormant Projects (Contd..7), H2 2016 401
Systemic Lupus Erythematosus - Dormant Projects (Contd..8), H2 2016 402
Systemic Lupus Erythematosus - Discontinued Products, H2 2016 403
Systemic Lupus Erythematosus - Discontinued Products (Contd..1), H2 2016 404

List of Figures
Number of Products under Development for Systemic Lupus Erythematosus, H2 2016 22
Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H2 2016 23
Number of Products under Development by Companies, H2 2016 24
Number of Products under Investigation by Universities/Institutes, H2 2016 29
Comparative Analysis by Late Stage Development, H2 2016 30
Comparative Analysis by Clinical Stage Development, H2 2016 31
Comparative Analysis by Early Stage Products, H2 2016 32
Assessment by Monotherapy Products, H2 2016 118
Number of Products by Top 10 Targets, H2 2016 120
Number of Products by Stage and Top 10 Targets, H2 2016 120
Number of Products by Top 10 Mechanism of Actions, H2 2016 125
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 125
Number of Products by Routes of Administration, H2 2016 130
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 130
Number of Products by Top 10 Molecule Types, H2 2016 132
Number of Products by Stage and Top 10 Molecule Types, H2 2016 132

【レポートのキーワード】

全身性エリテマトーデス

★調査レポート[全身性エリテマトーデス:治療薬開発パイプライン動向(2016年下半期版)] (コード:DATA70209295)販売に関する免責事項を必ずご確認ください。
★調査レポート[全身性エリテマトーデス:治療薬開発パイプライン動向(2016年下半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆